The Role of Adjuvant Endocrine Treatment in ER+, PR-, HER2- Early Breast Cancer: a Retrospective Study of Real-world Data

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 2

PMID 39487260

Authors

Miaochun Zhong

Xiaoqiu Ren

Wenjie Xia

Yangyang Qian

Kewang Sun

Jun Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: Estrogen receptor-positive (ER+), progesterone receptor-negative (PR-) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) often developed resistance to endocrine treatment (ET). We aimed to explore (1) the different clinicopathological features between ER+/PR+/HER2- and ER+/PR-/HER2- BC, and (2) whether ER+/PR-/HER2- early BC patients could benefit from adjuvant ET.

Methods: All patients treated for ER+/HER2- early BC who underwent surgery between 2010 and 2021 from a BC database in China were retrospectively examined. The cases followed up for less than six months were excluded.

Results: The records of ER+/PR+/HER2- (n = 10843) and ER+/PR-/HER2- BC (n = 1193) cases were reviewed, with median follow-up times of 35.8 and 47.0 months, respectively. Compared with ER+/PR+/HER2- cases, ER+/PR-/HER2- BC occurred more in postmenopausal women (73.1% vs. 52.9%, p = 0.000) and were more likely to be T > 2 cm (40.6% vs. 37.6%, p = 0.048) and Ki67 > 20%+ (48.1% vs. 36.9%, p = 0.000). However, ER+/PR-/HER2- cases had fewer nodal involvement (32.9% vs. 36.9%, p = 0.000). Approximately 82.2% (981/1193) of ER+/PR-/HER2- patients received ET, while approximately 17.8% (212/1193) did not. Compared to patients did not receive adjuvant ET, the ET group had similar disease-free survival (DFS) (HR = 1.33, 95% confidence interval (CI): 0.68-2.59, p = 0.444) and overall survival (OS) (HR = 1.17, 95%CI: 0.37-3.68, p = 0.799). 65.7% of recurrent ER+/PR-/HER2- patients experienced distant relapse (65.7% vs. 48.2% (for ER+/PR + cases), p = 0.011). By comparison, recurrent ER+/PR+/HER2- patients were more likely to experience only local relapse (31.6% vs. 14.9% (for ER+/PR- cases), p = 0.007).

Conclusions: ER+/PR-/HER2- BC was a special subtype with aggressive clinicopathological features and more tend to have distant metastasis rather than nodal involvement or local relapse. ER+/PR-/HER2- early BC did not seem to benefit from adjuvant ET.

References

Bae S, Kim S, Lee J, Lee H, Lee S, Kil W . Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015; 15:138. PMC: 4396721. DOI: 10.1186/s12885-015-1121-4. View

Dauphine C, Moazzez A, Neal J, Chlebowski R, Ozao-Choy J . Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. Ann Surg Oncol. 2020; 27(12):4687-4694. DOI: 10.1245/s10434-020-08898-5. View

Ng C, Pathy N, Taib N, Ho G, Mun K, Rhodes A . Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?. Asian Pac J Cancer Prev. 2014; 15(18):7959-64. DOI: 10.7314/apjcp.2014.15.18.7959. View

Dai D, Wu H, Zhuang H, Chen R, Long C, Chen B . Genetic and clinical landscape of ER + /PR- breast cancer in China. BMC Cancer. 2023; 23(1):1189. PMC: 10696783. DOI: 10.1186/s12885-023-11643-2. View

Mohammed H, Russell I, Stark R, Rueda O, Hickey T, Tarulli G . Progesterone receptor modulates ERα action in breast cancer. Nature. 2015; 523(7560):313-7. PMC: 4650274. DOI: 10.1038/nature14583. View

Cui X, Schiff R, Arpino G, Osborne C, Lee A . Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005; 23(30):7721-35. DOI: 10.1200/JCO.2005.09.004. View

Liu X, Ma D, Xu X, Jin X, Yu K, Jiang Y . Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. Theranostics. 2019; 8(22):6386-6399. PMC: 6299689. DOI: 10.7150/thno.29164. View

Hu T, Chen Y, Liu Y, Zhang D, Pan J, Long M . Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores. BMC Med Res Methodol. 2021; 21(1):108. PMC: 8141178. DOI: 10.1186/s12874-021-01297-8. View

Moon Y, Park S, Sohn J, Kang D, Koo J, Park H . Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011; 137(7):1123-30. DOI: 10.1007/s00432-011-0976-2. View

10.

Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X . Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One. 2014; 9(8):e95629. PMC: 4149365. DOI: 10.1371/journal.pone.0095629. View

11.

Park C, Park K, Kim J, Sin Y, Park I, Cho H . Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. World J Surg Oncol. 2016; 14(1):244. PMC: 5020449. DOI: 10.1186/s12957-016-0999-x. View

12.

Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H . Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. Oncologist. 2018; 24(2):165-171. PMC: 6369957. DOI: 10.1634/theoncologist.2018-0176. View

13.

Feeley L, Mulligan A, Pinnaduwage D, Bull S, Andrulis I . Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2013; 27(4):554-61. DOI: 10.1038/modpathol.2013.153. View

14.

van Mackelenbergh M, Denkert C, Nekljudova V, Karn T, Schem C, Marme F . Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2017; 167(1):59-71. DOI: 10.1007/s10549-017-4480-5. View

15.

Luo Y, Li Q, Fang J, Pan C, Zhang L, Xu X . ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024; 14(1):197. PMC: 10761672. DOI: 10.1038/s41598-023-50755-4. View

16.

Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y . Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2020; 3(1):e1918160. PMC: 6991239. DOI: 10.1001/jamanetworkopen.2019.18160. View

17.

Li Z, Tu Y, Wu Q, Wang Z, Li J, Zhang Y . Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases. Clin Breast Cancer. 2019; 20(2):e151-e163. DOI: 10.1016/j.clbc.2019.07.002. View

18.

Fei F, Siegal G, Wei S . Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers. Clin Breast Cancer. 2022; 22(7):e788-e797. DOI: 10.1016/j.clbc.2022.07.001. View

19.

Zhang M, Yan M, Lv H, Niu L, Zeng H . Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer. Ann Palliat Med. 2021; 10(1):238-243. DOI: 10.21037/apm-20-2180. View

20.

Arpino G, Weiss H, Lee A, Schiff R, De Placido S, Osborne C . Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97(17):1254-61. DOI: 10.1093/jnci/dji249. View